Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

London, UK

Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.

Latest From Andrew McConaghie

Novo Nordisk UK In Trouble Again, This Time For Failing To Disclose Payments

Already suspended from the UK industry association, the company has been publicly reprimanded for not revealing £7.8m in payments over three years.

Ad Complaints Metabolic Disorders

SciRhom Secures €63m Series A To Target Autoimmune Disease ‘Master Switch’

The Munich-based firm looks to pioneer the novel iRhom2 mechanism to dial down inflammation while maintaining immune homeostasis.

Commercial Financing

Roche’s Susvimo Returns, But Destined To Be Vabysmo’s Support Act

The implantable eye treatment will be back on the market soon, but risk of eye infections and complications remain higher than with injectable treatments, meaning it will play second fiddle to Vabysmo.

Approvals Ophthalmic

Novo Nordisk UK In Trouble Again, This Time For Failing To Disclose Payments

Already suspended from the UK industry association, the company has been publicly reprimanded for not revealing £7.8m in payments over three years.

Commercial Companies

Roche’s SKYSCRAPER-06 Failure Is Another Blow For TIGIT

It is not all over for Roche’s hopes for tiragolumab in frontline NSCLC but it may soon be.

Commercial Companies

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

See All
UsernamePublicRestriction

Register